The association between CD4+ CD25+ regulatory T cells and non-small cell lung carcinoma

Baecher-Allan C, Anderson DE (2006) Regulatory cells and human cancer. Sem Cancer Biol 16:98–105

Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, Pak PS, Elashoff D, Reckamp K, Zhang L, Fishbein MC, Sharma S, Dubinett SM (2010) PGE2 contributes to TGF-β induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res 2(4):356–367

Barthelemy-Brichant N, David JL, Bosquee L, Bury T, Seidel L, Albert A, Bartsch P, Baugnet -Mahieu L, Deneufbourg JM (2002) Increased TGF-β1 plasma level in patients with lung cancer: potential mechanisms. Eur J Clin Invest 32:193–198

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949

Dawson B, Trapp RG (2001) Basic and clinical biostatistics, 3rd edn. McGraw-Hill, New York

De Visser KE, Kast WM (1999) Effects of TGF-b on the immune system: implications for cancer immunotherapy. Leukemia 13:1188–1199

Dubinett S, Sharma S, Huang M, Mao JT, Batra R (2004) Cancer and immune dysfunction. In: Finke J, Bukowski R (eds) Immunotherapy at the crossroads: how tumors evade immunity and what can be done. Human Press Inc., Totowa, pp 335–350

Eikawa S, Ohue Y, Kitaoka K, Aji T, Uenaka A, Oka M, Nakayama E (2010) Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8 expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 185(11):6734–6740

Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, Amani D (2012) Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 77(2):306–311

Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW (2011) Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother 60(9):1227–1242

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96

Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, Li J, Zhang Y, Liu L, Ge Y, Johnson DE, Ju S, Shu Y (2009) CD13+ CD4+ CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. Cell Cycle 8(16):2578–2585

Karagöz B, Bilgi O, Gümüs M, Erikçi AA, Sayan O, Türken O, Kandemir EG, Oztürk A, Yaylaci M (2010) CD8+CD28− cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol 27(1):29–33

Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353–362

Klehmet J, Harms H, Richter M, Prass K, Volk HD, Dirnagl U, Meisel A, Meisel C (2009) Stroke induced-immunosupression and post stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience 158:1184–1193

Leber A, Teles A, Zenclussen AC (2010) Regulatory T cells and their role in pregnancy. Am J Reprod Immunol 63:445–459

Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C (2007) Tumor evasion of the immune system by converting D4+ CD25− T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-β. J Immunol 178:2883–2892

Liyanage UK, Moore TT, Hong-Gu, Joo HG, Tanaka Y, Herrmann V et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761

Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, Eberlein TJ, Goedegebuure PS, Linehan DC (2009) Tumor-derived TGF-beta mediates conversion of CD4+ Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother 32:12–21

Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi M-B, Harpole DH Jr, Patz EF Jr (2006) Tumor infiltrating FOXP3+ regulatory T cells are associated with recurrence in pathologic stage I NSCLC. Cancer 107:2866–2872

Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101:455–458

Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4+ CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98:1089–1099

Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM (2005) Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 65(12):5211–5220

Shevach EM (2000) Regulatory T cells in autoimmunity. Annu Rev Immunol 18:423–449

Sutmuller RP, van Duivenvoorde LM, van Elsas A et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823–832

Thornton AM, Shevach EM (1998) CD4+ CD25+ immunoregulatory T cells suppress polyclonal T-cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287–296

Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F (2005) Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352:2589–2597

Wong SF, Lai LC (2001) The role of TGF-beta in human cancer. Path 33:85–92

Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61(12):4766–4772

Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272–4276

World Medical Association (2008) Declaration of Helsinki. Ethical principles for medical research involving human subjects, the 59th WMA General Assembly, Seoul, South Korea

Xue L, Chen J, Peng JZ, Chen BS, Hua P, Yang YQ (2009) Clinical significance of tumor interstitial T lymphocyte subset activity in non-small-cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao 29(12):2456–2458

Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H et al (2006) Increase of CD4+ CD25+ regulatory T cells in the liver of patients with hepatocellular carcinoma. J Hepatol 45:254–262

Yoshino I, Yano T, Murata M et al (1992) Tumor-reactive Tcells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res 52:775–781